Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis

. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2

	Effect vs placebo  Class NWMA		Effect vs placebo  Sensitivity analysis		Rank
Class	Median	95% CrI	Median	95% CrI	Mean	Median	95% CrI	Pr (best)
LABA/ICS	‐3.60	(‐4.63 to ‐2.34)	‐3.53	(‐4.69 to ‐2.15)	1.2	1	(1 to 3)	0.86
LAMA	‐2.50	(‐3.30 to ‐1.68)	‐2.56	(‐3.49 to ‐1.69)	2.9	3	(1 to 4)	0.04
LABA	‐2.55	(‐3.68 to ‐1.70)	‐2.61	(‐3.82 to ‐1.68)	2.8	3	(1 to 4)	0.07
ICS	‐2.34	(‐3.45 to ‐1.27)	‐2.34	(‐3.58 to ‐1.16)	3.2	3	(1 to 4)	0.03
^aFor effects versus placebo, smaller values indicate larger benefits of the active treatment Crl = credible interval. SGRQ = St George's Respiratory Questionnaire. ICS = inhaled corticosteroid. LABA = long‐acting beta₂‐agonist. LABA/ICS = long‐acting beta₂‐agonist/inhaled corticosteroid. LAMA = long‐acting antimuscarinic antagonist. NWMA = network meta‐analysis. Pr = probability.